株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

症候性検査市場

Syndromic Testing Markets

発行 Kalorama Information 商品コード 876846
出版日 ページ情報 英文 37 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
症候性検査市場 Syndromic Testing Markets
出版日: 2019年05月30日 ページ情報: 英文 37 Pages
概要

当レポートでは、世界の症候性検査市場を調査し、主な症候性検査パネル、GI症候性検査市場、呼吸器症候性検査市場、HAI症候性検査パネル、その他の症候性検査市場、および市場予測に関するデータ、ならびに主要企業のプロファイルを提供しています。

第1章 エグゼクティブサマリー

第2章 市場サマリー

  • ベンダー活動
  • 症候性検査における近年の発展
    • 不必要な抗生物質処方薬の継続的な使用
    • 大規模な高齢者・免疫不全集団
    • MeridianがGenePOCの買収により症候性市場へ参入
    • 前向きな研究が有益性を実証
    • 混合感染
    • 食中毒の増加
  • 市場規模:症状別
  • 症候性検査

第3章 企業プロファイル

  • ABBOTT LABORATORIES
  • AKONNI BIOSYSTEMS
  • BECTON, DICKINSON AND COMPANY (BD)
  • BIOCARTIS NV
  • BIOMERIEUX INC.
  • MERIDIAN BIOSCIENCE, INC.
  • QIAGEN N.V.
  • SIEMENS HEALTHINEERS
目次
Product Code: 19-094

Saving sample volume, cutting down provider time, reducing costs, improving outcomes, these are goals of the healthcare system, and they are well suited to a test that can identify more than a single pathogen. It has been thought that numerous pathogens tested directly from clinical specimens could change up diagnostics, and many vendors have responded by producing syndromic multiplex panels with considerable capabilities. These single tests, designed to detect a number of organisms that might have caused a particular syndrome, are aimed at positively influencing decisions regarding patient management, infection control, and antimicrobial prescription decisions. On a more fundamental level- they can produce better test results, as they tend to find infections at a greater rate.

This Kalorama Information report includes the following important business data:

  • Selected Syndromic Test Panels
  • Market for GI Syndromic Tests
  • Market for Respiratory Syndromic Tests
  • Market for HAI Syndromic Test Panels
  • Market for Other Syndromic Testing
  • Forecasts to 2023
  • Company Profiles

It is increasingly common to test in panels to gain clarity on disease while treatment will be most effective. Numerous multiplex products are on the market, and their effectiveness has been shown in studies, but there are challenges with reimbursement. Syndromic tests offer benefits and many studies prove their worth, but there are challenges. The tests by nature test for more than the disease-causing pathogen and can increase overall costs. Despite this, used right they can lower costs. There is a substantial market and it is expected that as workarounds for the new payor issues are developed growth can proceed. These issues are covered in this report.

As of 2019, over 40 companies are active in the global market for liquid biopsy diagnostics and monitoring tests. The market for liquid biopsy testing, still in its infancy, is rapidly evolving as vendors develop and commercialize innovative new technologies to meet the needs of the clinical diagnostic market.

Geographically, the majority of participants in the liquid biopsy market are based in the United States, and to a lesser extent, Europe. A few companies are based in Asia. The competitive landscape is quite varied, with participants ranging from some of the world's largest and most well-established diagnostics companies to small start-ups; Kalorama's report provides extensive landscaping

With the growing number of market entrants and available tests, competition is increasing. In the past two years, several new competitors entered the market, while several others have exited. However, with the rapidly growing market the heterogeneity of cancer as an umbrella term for many diseases, there are ample opportunities in the market to meet the needs of clinicians and patients. Kalorama's report tracks these trends, identifies segment markets and separates research markets from those involving the detection and monitoring of disease.

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

  • SYNDROMIC TESTING
  • ADVANTAGES OF SYNDROMIC TESTING
  • CHALLENGES OF SYNDROMIC TEST APPROACHES
  • SCOPE AND METHODOLOGY
  • SIZE AND GROWTH IN THE MARKET
    • Figure 1-1: Market for Syndromic Testing, 2018 - 2023

CHAPTER TWO: MARKET SUMMARY

  • VENDOR ACTIVITY
    • Table 2-1: Selected Syndromic Test Platforms
  • RECENT DEVELOPMENTS IN SYNDROMIC TESTING
    • Continued Unnecessary Antibiotic Prescription Use
    • Large Elderly and Immunocompromised Population
    • Meridian Enters Syndromic With GenePOC Acquisition
    • Positive Studies Demonstrate Benefits
    • Mixed Infections
    • Rising Foodborne Infections
  • SIZE OF THE MARKET BY INDICATION
    • Table 2-2: Syndromic Testing by Type (HAI, Respiratory, GI Testing, Others) 2018-2023 (millions)
  • SYNDROMIC TESTING POST-PALMETTO DECISION

CHAPTER THREE: COMPANY PROFILES

  • ABBOTT LABORATORIES
    • Overview
    • Infectious Disease IVD Products
  • AKONNI BIOSYSTEMS
  • BECTON, DICKINSON AND COMPANY (BD)
    • Overview
    • Infectious Disease IVD Products
  • BIOCARTIS NV
  • BIOMÉRIEUX INC.
    • Overview
    • Infectious Disease IVD Products
  • MERIDIAN BIOSCIENCE, INC.
    • Overview
    • Infectious Disease IVD Products
  • QIAGEN N.V.
    • Overview
    • Infectious Disease IVD Products
    • QIAstat-Dx
  • SIEMENS HEALTHINEERS
    • Overview
    • Infectious Disease IVD Products
Back to Top